Let's break down Ajanta Pharma Limited (AJANTPHARM) — from its financial performance to how the market is valuing the stock.
Ajanta Pharma Revenue Trend
Ajanta Pharma Limited reported revenue of ₹5,453 Cr in FY2026, a 17.3% increase from ₹4,648 Cr in FY2025.
A 12.2% CAGR over 10 years puts Ajanta Pharma Limited in solid growth territory. The top line went from ₹1,728 Cr to ₹5,453 Cr in that span.
A ₹5,453 Cr revenue base makes Ajanta Pharma Limited a mid-sized name in the Indian pharmaceuticals sector.
With 7 straight years of revenue growth, this isn't a blip — the trajectory is clear for Ajanta Pharma Limited.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹5,453 Cr | +17.3% |
| FY2025 | ₹4,648 Cr | +10.4% |
| FY2024 | ₹4,209 Cr | +12.5% |
| FY2023 | ₹3,743 Cr | +12.0% |
| FY2022 | ₹3,341 Cr | — |
View Ajanta Pharma Limited's full 10-year revenue trend with CAGR analysis →
Ajanta Pharma Profitability
Ajanta Pharma Limited's bottom line improved to ₹1,056 Cr in FY2026, a 14.7% increase over the prior year.
The company maintained its net margin at 19.4% in FY2026, roughly in line with the prior year.
Per-share earnings moved to ₹84.51 in FY2026 from ₹73.53 in FY2025.
Is Ajanta Pharma Undervalued
Ajanta Pharma Limited shares are currently trading at ₹3,513.90.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Ajanta Pharma Shareholding Pattern
Promoters trimmed their stake from 66.2% to 63.5% over the last 4 quarters.
FII holding stands at 7.7%, down from 8.5% in the year-ago quarter.
DII holding is at 21.8%, up from 17.9% in the year-ago quarter.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 63.5% | 7.7% | 21.8% | 7.0% |
| Mar 2026 | 66.2% | 8.3% | 18.4% | 7.1% |
| Dec 2025 | 66.2% | 8.0% | 18.6% | 7.2% |
| Sep 2025 | 66.2% | 8.5% | 17.9% | 7.3% |
Track quarterly shareholding changes for Ajanta Pharma Limited →
Ajanta Pharma Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2026 total assets: ₹61.55B (up 22.7% YoY from ₹50.15B).
Top categories: Property, Plant & Equipment (32.2%), Receivables (30.1%), Inventories (15.2%).
Of the ₹61.55B in liabilities and equity, 73.6% is shareholder equity, 4.2% is interest-bearing debt, and 22.2% is operating liabilities. Over the year, debt is up 448.7% and equity is up 19.4%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 6.63B |
| Receivables | 18.54B |
| Inventories | 9.39B |
| Property, Plant & Equipment | 19.84B |
| Investments | 285.00M |
| Intangibles & Goodwill | 415.80M |
| Other Assets | 6.45B |
| Category | Value |
|---|---|
| Equity | 45.27B |
| Short-term Debt | 2.21B |
| Long-term Debt | 394.20M |
| Trade Payables | 5.44B |
| Other Liabilities | 8.23B |
Ajanta Pharma Stock Analysis
To sum up Ajanta Pharma Limited's financial position: the data paints a clear picture for investors evaluating this pharmaceuticals stock.
Revenue of ₹5,453 Cr in FY2026, up 17.3% year-over-year.
Long-term revenue has been compounding at 12.2% annually over 10 years.
The company is profitable, with a net margin of 19.4% and net income of ₹1,056 Cr.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Ajanta Pharma Limited.